Loading...
Loading...
INSM| Name | Value |
|---|---|
| Revenues | 75.5M |
| Cost of Revenue | 18.7M |
| Gross Profit | 56.8M |
| Operating Expense | 214.2M |
| Operating I/L | -157.4M |
| Other Income/Expense | 0.9M |
| Interest Income | 0.8M |
| Pretax | -156.5M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -157.1M |
Insmed Incorporated is a biopharmaceutical company specializing in the development and commercialization of therapies for patients with serious and rare diseases. The company's flagship product, ARIKAYCE, is used in the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. Additionally, Insmed is developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, as well as Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
